SEC Form 4 · accession 0001209191-17-041636
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Biller
Officer — Chief Scientific Officer
Period of report
Jun 21, 2017
Accepted (ET)
Jun 23, 2017 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Jun 21, 2017 | M | 4,292 | $9.05 | A | 4,556 | D | |
| Common stockF2 | Jun 21, 2017 | S | 4,292 | $55.00 | D | 264 | D | |
| Common stockF2 | Jun 21, 2017 | M | 3,000 | $0.4675 | A | 3,264 | D | |
| Common stockF4 | holding | — | — | — | 46,470 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F5 | $9.05 | Jun 21, 2017 | M | 4,292 | D | — | Apr 29, 2023 | Common stock | 4,292 | 41,719 | D |
| Stock option (right to buy)F6 | $0.4675 | Jun 21, 2017 | M | 3,000 | D | — | Dec 6, 2020 | Common stock | 3,000 | 17,875 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This amount excludes 15,470 shares of common stock which were transferred on June 14, 2017 to a spousal lifetime access trust, of which the reporting person's wife is trustee.
- F3This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F4Shares held by a spousal lifetime access trust, of which the reporting person's wife is trustee. This amount includes 15,470 shares of common stock which were transferred on June 14, 2017 from the reporting person's direct holdings.
- F5This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.
- F6This option was granted on December 7, 2010. The shares underlying this option vest as to 25% of the shares on September 20, 2011, with the remaining 75% vesting in 36 equal monthly installments thereafter.